Welcome to our dedicated page for Moolec Science SEC filings (Ticker: MLEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moolec Science SA filings document a foreign private issuer developing molecular farming and precision fermentation technologies for food-ingredient applications. Its Form 6-K reports and annual materials cover shareholder meeting matters, consolidated financial statements, board composition, Nasdaq continued-listing compliance, share consolidation, and incorporation of certain reports into its Form S-8 registration statement.
The filing record also documents capital-structure and control matters, including preference-share conversion and the emergence of a controlling shareholder, as well as accounting disclosures related to loss of control and derecognition of subsidiaries following bankruptcy proceedings. These disclosures frame the company’s governance, ownership, reporting status, and public-company obligations alongside its operating business.
Moolec Science S.A. received a decision from a Nasdaq Hearings Panel granting an exception through June 29, 2026 to regain compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The company reports that the bankruptcy of certain subsidiaries triggered loss-of-control derecognition events under IFRS, leading to estimated gains of approximately $91.0 million for Bioceres S.A., $5.2 million for Bioceres LLC, and $4.6 million for Theo I SCSp.
Together with recognition of intercompany assets and liabilities and conversion of certain preference shares into ordinary shares, these items increased Moolec’s stockholders’ equity. Based on this, Moolec believes it has regained compliance with Nasdaq’s equity standard and has notified Nasdaq, while stating it will continue taking actions to maintain ongoing listing compliance.
Moolec Science SA reported the results of a virtual extraordinary general meeting held on December 16, 2025. Shareholders representing 4,804,341 ordinary shares out of 10,891,761 entitled to vote, or 44.110% of the company’s outstanding ordinary shares, were present in person or by proxy.
Shareholders approved an ordinary resolution authorizing a share consolidation at a ratio between 1-for-10 and 1-for-25, with the exact ratio and an effective date between December 17, 2025 and May 14, 2026 to be set later by the board. After the consolidation, every 10 to 25 existing ordinary shares will be combined into 1 new ordinary share, and any fractional shares will be rounded up to the nearest whole share.
They also passed a special resolution to adopt amended and restated memorandum and articles of association immediately following the effective date, to reflect the consolidation and the rights and terms of the post-consolidation ordinary shares.
Moolec Science SA reported that Nasdaq issued a determination letter stating its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days and that it would not automatically receive the usual 180‑day grace period to regain compliance. Moolec has appealed to a Nasdaq Hearings Panel, asking for a 180‑day period to implement a compliance plan, which may include a reverse stock split if deemed in shareholders’ best interests. The appeal temporarily halts the determination letter, so the shares continue to trade on the Nasdaq Capital Market under the symbol "MLEC" while the appeal is heard on December 18, 2025. The company states that this listing issue does not affect its underlying business, operations, or SEC reporting obligations.
Moolec Science (MLEC) reported a potential contract dispute with INVIM. The company received a notice of alleged breach on October 2, 2025 related to an Assignment and Assumption Agreement tied to prior transaction instruments. INVIM asserts the Obligors failed to pay an Assignment Price of $13 million due on September 30, 2025.
Moolec disagrees, stating certain conditions precedent were never satisfied, including transfer of relevant securities and execution of a required services agreement. The company sent a formal response on October 20, 2025 rejecting the assertions and reserving all rights. Moolec intends to defend its position, noting that an adverse outcome, if INVIM ultimately prevails, could have a material adverse effect on its business, financial condition, results of operations, or liquidity.